An open-label, MRCT phase I/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors

CBP-1019 - Coherent Biopharma

D. Liu1; L. Shen1; Y. Sun2; N. Li3; O. Marathe4; R. Huang5; J. Shao5; M. Xu6; B. Pan6; F. Pan5; S. Gao6; J. Gong1

Jul 25, 2024